Emblem to Develop Oral Sustained Release Product for Cannabinoids

Visit the Emblem Corp Investor Dashboard and stay up to date with data-driven, fact based due diligence for active traders and investors.

Emblem Announces Exclusive Agreement with Canntab Therapeutics for Cannabinoid Based Oral Sustained Release Formulation

PARIS, Ontario, Oct. 03, 2017 (GLOBE NEWSWIRE) — Emblem Corp. (TSXV:EMC)

... read more at: https://www.newcannabisventures.com/emblem-to-develop-oral-sustained-release-product-for-cannabinoids/